Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04729803
Other study ID # STUDY00000106
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 18, 2021
Est. completion date June 30, 2022

Study information

Verified date January 2024
Source University of Texas at Austin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study involves completing some online assessments and an intervention for social anxiety that all involve interactions with other people on a teleconferencing call.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date June 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age 18-75 - Fluent in English because the data collection materials have not yet been standardized in other languages - Having access to a computer with a webcam and ability to record audio - Personal Report of Communication Apprehension > 80 - Leibowitz Social Anxiety Scale > 30 - Meets DSM-5 Criteria for Social Anxiety Disorder Exclusion Criteria: - Significant visual impairment precluding the use of the eye tracking equipment - Current, or history of bipolar disorder; current, or history of psychosis

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Experimental: Attention Guidance + Exposure
Participants will receive a brief standardized psychoeducation module, presented via a video recording. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. Between speeches participants will have a 1-minute break. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial. The experimental attention guidance condition: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given target audience members to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target audience member for the whole response.
Active Comparator: Exposure Alone
Participants will receive a brief standardized psychoeducation module, presented via a video recording. Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. Between speeches participants will have a 1-minute break. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial.
Experimental: Attention Control + Exposure
Participants will receive a brief standardized psychoeducation module, presented via a video recording. F Participants will then complete up to 10 analogue teleconferencing calls, each lasting a maximum of two minutes. During each call participants will be prompted by one of the audience members. Between speeches participants will have a 1-minute break. Participants will complete the subjective units of distress scale (SUDS) before and after each speech trial. The experimental attention control condition: (1) the intervention rationale will include information about the importance of attention control; (2) participants will be given target at the center of the screen to focus their gaze on during the their impromptu response. They will be told that they should look at and focus on the target for the whole response.

Locations

Country Name City State
United States Laboratory for the Study of Anxiety Disorders, University of Texas at Austin Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas at Austin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Personal Report of Communication Apprehension Questionnaire Assessment of communication concerns, range of scores is 24-120; higher scores are worse prior to the first treatment session, an average of 2 days
Primary Personal Report of Communication Apprehension Questionnaire Assessment of communication concerns, range of scores is 24-120; higher scores are worse 1-week follow-up
Primary Personal Report of Communication Apprehension Questionnaire Assessment of communication concerns, range of scores is 24-120; higher scores are worse 2-week follow-up
Primary Leibowitz Social Anxiety Scale Questionnaire Assessment of general social anxiety, range of scores is 0-144; higher scores are worse prior to the first treatment session, an average of 2 days
Primary Leibowitz Social Anxiety Scale Questionnaire Assessment of general social anxiety, range of scores is 0-144; higher scores are worse 1-week follow-up
Primary Leibowitz Social Anxiety Scale Questionnaire Assessment of general social anxiety, range of scores is 0-144; higher scores are worse 2-week follow-up
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06274112 - Using TMS to Understand Neural Processes of Social Motivation N/A
Completed NCT02554929 - Treatment of Social Anxiety Disorder and Selective Mutism N/A
Completed NCT00684541 - Interpretation Modification Program for Social Phobia N/A
Completed NCT00684320 - Attention Disengagement Training for Social Phobia N/A
Completed NCT03247075 - Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT N/A
Completed NCT02811458 - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders N/A
Withdrawn NCT04622930 - Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD) N/A
Active, not recruiting NCT05018312 - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety N/A
Active, not recruiting NCT05124639 - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders N/A
Completed NCT05858294 - The Safety, Acceptability and Efficacy of Alena N/A
Active, not recruiting NCT05600114 - Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Not yet recruiting NCT02924610 - Brief Intervention to Reduce Fear Phase 4
Active, not recruiting NCT02592564 - Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder N/A
Recruiting NCT02305537 - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment N/A
Terminated NCT03764644 - Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders N/A
Unknown status NCT01712321 - Study of Vilazodone to Treat Social Anxiety Disorder N/A
Completed NCT01320800 - CBT for Social Anxiety Disorder Delivered by School Counselors Phase 2
Completed NCT00485615 - An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia Phase 2
Completed NCT00773162 - Flushing in Social Anxiety Disorder on Seroquel Phase 3